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Despite the availability of anti-hypertensive medications with increasing efficacy up to 50%
of hypertensive patients have blood pressure levels (BP) not at the goals set by international
societies. Some of these patients are either not optimally treated or are non-adherent to
the prescribed drugs. However, a proportion, despite adequate treatment, have resistant
hypertension (RH), which represents an important problem in that it is associated to an
excess risk of cardiovascular events. Notwithstanding a complex pathogenesis, an abun-
dance of data suggests a key contribution for the mineralocorticoid receptor (MR) in RH,
thus fostering a potential role for its antagonists in RH. Based on these premises random-
ized clinical trials aimed at testing the efficacy of MR antagonists (MRAs) in RH patients
have been completed. Overall, they demonstrated the efficacy of MRAs in reducing BP and
surrogate markers of target organ damage, such as microalbuminuria, either compared to
placebo or to other drugs. In summary, owing to the key role of the MR in the pathogenesis
of RH and on the proven efficacy of MRAs we advocate their inclusion as an essential com-
ponent of therapy in patients with presumed RH. Conversely, we propose that RH should
be diagnosed only in patients whose BP values show to be resistant to an up-titrated dose
of these drugs.
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RESISTANT HYPERTENSION: WANDERING DEFINITIONS ARE
NOT HELPFUL
The development of novel anti-hypertensive medications with
increasing efficacy and decreasing adverse effects might generate
the deceitful impression that decreasing patients’ blood pressure
(BP) at the goals set by international societies is no longer an issue.
By contrast, available data indicate just the opposite, as recently
confirmed by an analysis of the National Health and Nutrition
Examination Survey (NHANES) showing that only 53% of treated
hypertensive participants had BP at goal (1), as well as by a cross-
sectional analysis of the Framingham Heart Study and a recent
study including 172,432 subjects in which only from 48 to 64% of
treated patients had BP at goal (2, 3). While differences in these
rates (7.6–18%) likely reflect several factors, including, above all,
the stringency of the criteria used (4, 5), it is clear that not all of the
hypertensive patients with uncontrolled BP values have resistant
hypertension (RH) and represent therapeutic failures. Good deals
of them are either not optimally treated (6) or are non-adherent
to the prescribed drugs (7–9) or are taking medications that can
raise BP [see for review Rossi et al. (10)]. Therefore, they should
be more appropriately considered medical failures. However, the
subset of patients that have RH according to the definitions of the
international societies (Table 1) represent an important medical
problem as they are exposed to progressive damage in the target
organs (11) and thereby to an excess risk of cardiovascular events
as recently reemphasized by a post hoc analysis of the ALLHAT
database (12).
All the current guidelines define RH, albeit with slight differ-
ences (Table 1), by the inability to lower BP levels at goal with a
treatment including at least three drugs of different classes, one
being ideally (13) or necessarily (14–16) a diuretic, all prescribed
at optimal doses. The American Heart Association (AHA) defini-
tion is even less restrictive in that it defines as RH patients those
on more than three medications, even though their BP is at target
(13). It is worth to underline that only the European Society of
Hypertension (ESH) guidelines pay heed to the implementation
of appropriate lifestyle changes (14), a treatment option neglected
in the others (13, 15, 16). The measures associated to a better BP
control are: (1) salt restriction [systolic and diastolic BP reduc-
tion of 6/3 mmHg up to 20/10 mmHg, respectively (17)]; (2) diet
reduced on saturated fat/cholesterol and increased on vegetables,
fruits, and fish [5/3 mmHg of systolic and diastolic BP reduction,
respectively (18)]; (3) weight reduction [1 mmHg of BP decrease
per kilogram of weight loss (19)]; (4) aerobic physical exercise
[7/5 mmHg of systolic and diastolic BP reduction, respectively
(20)]; (5) limitation of alcohol consumption [1.9/0.6 mmHg of
systolic and diastolic BP reduction, respectively (21)]; (6) smok-
ing cessation (22) (Table 2). The highlighting of lifestyle measures
by the ESH guidelines is commendable, but should be interpreted
as appropriate counseling given to patients. Nonetheless, strict
application of this definition implies that subjects non-compliant
with these directions, just like those non-compliant to medical
treatment, would not meet the criteria for RH.
The three major international societies (13, 14, 16) do not spec-
ify the drugs in their definition of RH, while the British NICE
dictates the classes of medications, which are an angiotensin con-
verting enzyme inhibitor (ACE-I) or an angiotensin II receptor
blocker (ARB), a calcium channel blocker (CCB), and a diuretic
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Table 1 | Definitions of resistant hypertension according to major
scientific societies.
Society/year/
reference
Definition
Seventh JNC
2003 (16)
Blood pressure above goal
Adhesion to full doses of an appropriate three-drug
regimen
One of the three agents is necessarily a diuretic
AHA Scientific
Statement 2008
(13)
Blood pressure above goal in spite of the concurrent
use of three antihypertensive agents of different
classes
One of the three agents ideally should be a diuretic
Patients whose blood pressure is controlled but
requires four or more medications
NICE Guidelines
2011 (15)
Blood pressure higher than 140/90 mmHg after
treatment with optimal or best tolerated doses of
drugs
Drug therapy including an ACE inhibitor or an ARB
combined with a calcium channel blocker and a
diuretic
ESH/ESC
Guidelines 2013
(14)
Systolic and diastolic blood pressure values above 140
and 90 mmHg, respectively
Therapeutic strategy including lifestyle measures
Drug therapy including a diuretic and two other
antihypertensive drugs belonging to different classes
at adequate doses
Table 2 | Lifestyle changes associated to a BP decrease.
Salt restriction (6/3 mmHg up to 20/10 mmHg of systolic and diastolic BP
reduction, respectively)
Diet low on saturated fat/cholesterol and high on vegetables, fruits, fish
diet (5/3 mmHg of systolic and diastolic BP reduction, respectively)
Weight reduction (1 mmHg of BP decrease per kilogram of weight loss)
Aerobic physical exercise (7/5 mmHg of systolic and diastolic BP reduction,
respectively)
Limitation of alcohol consumption (1.9/0.6 mmHg of systolic and diastolic
BP reduction, respectively)
Smoking cessation
(15). Messerli et al. proposed an even more restrictive definition:
a systolic BP of 160 mmHg or higher despite treatment with a full
dose of a renin–angiotensin–aldosterone system (RAAS) blocker
(either an ACE-I, an ARB, or a renin inhibitor), a CCB (either dihy-
dropyridine or non-dihydropyridine), a diuretic (preferentially
chlorthalidone), and, if tolerated, a mineralocorticoid receptor
(MR) antagonist (MRA) (spironolactone or eplerenone) (23).
Such more strict criteria to define RH could be useful but carry
some limitations: patients not having BP at goal despite being
treated with more than three drugs, but with intolerance or con-
traindication to a class of drugs, such as, for example, a RAAS
blocker in subjects with bilateral renal artery stenosis, or a CCB in
those with low ejection fraction heart failure, would not meet the
definition for RH. Such incorrect classification of these patients,
can imply that they will not be perceived as being at high-risk, thus
affecting their management and prognosis and impairing data
comparability of cohort studies or clinical trials using different
definitions.
In summary, there is an urgent need to homogenize the defini-
tions of RH by including also the patients intolerant to the drugs
suggested by guidelines and experts (15, 23) if in need of more
than three drugs and with BP above goal.
RESISTANT HYPERTENSION: RELEVANCE OF THE ISSUE
Data from large clinical trials of anti-hypertensive therapy sug-
gest that the prevalence of RH can be as high as 35% (24–
29) (Table 3). These numbers are probably overestimated since
patients enrolled in these trials entail selected cohorts with risk
profile and comorbidities higher than the ordinary hypertensive
population.
Observational studies likely provide a more genuine estimate
of the actual figures involved and show that RH involves 10–20%
of the general population of hypertensive patients (30). However,
some drawbacks mandate caution in interpreting these data. For
instance, in a United States cohort, after exclusion of non-adherent
subjects, who can entail 37% of patients with uncontrolled hyper-
tension (8), a rate of RH of 12.8% was reported. However, the
assumption of diuretics, which for most guidelines represents a
condicio sine qua non-for the diagnosis, was neglected (31). More-
over, patients with white-coat syndrome, who can be up to 40%
of patients with “resistant hypertension” (4), were not excluded.
In another US study, Daugherty et al. found that the prevalence of
RH was 16.2%, but the same biases existed (32). Finally, a Span-
ish study that estimated a prevalence of RH of 8.9% and devoted
proper attention to exclude those with the white-coat effect did
not assess drug adherence (4). Of interest, two studies looking
specifically at the rate of RH provided quite different estimates.
According to Pierdomenico et al., who defined RH as office BP
≥140 or≥90 mmHg for systolic and diastolic, respectively, at least
at two visits while on triple therapy, the prevalence would be 18%
(5). By contrast, the Spanish ambulatory blood pressure monitor-
ing (ABPM) Registry that in similarly treated patients based the
definition on identical criteria for clinical BP but also used ABPM
daytime BP≥130 or≥80 mmHg for systolic and diastolic, respec-
tively, reported a prevalence of 7.6% (4). Hence, it is altogether
evident that ABPM is necessary to pinpoint those with clinic high
BP that is due to the white-coat phenomenon.
The attention that RH is receiving mainly derives from the
evidence that it associates not only with subclinical target organ
damage, such as left ventricular hypertrophy (11, 33, 34), microal-
buminuria (31, 33–36), impaired renal function (31, 34), and
vascular involvement revealed by carotid intima media thicken-
ing (11) exceeding that of patients with well controlled BP, but
also with a worse prognosis. These subjects are in fact exposed
to an excess risk of stroke, myocardial infarction, congestive heart
failure, and chronic kidney disease (12, 37). Indeed, while studies
comparing resistant and non-resistant hypertensives consistently
showed a higher risk in former, up to 50% (hazard ratio 1.47, 95%
confidence interval 1.33–1.62) of cardiovascular events and renal
events (5, 32, 38), the estimates of this excess risk are imprecisely
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Table 3 | Resistant hypertension prevalence in randomized controlled trials.
Study Pts (n°) Hypertensive Pts
characteristics
Definition RH Prevalence
of RH (%)
ALLHAT 14,684 ≥55 y/o Pts on ≥3 drug classes BP ≥140/90 mmHg OR pts ≥4 drug classes 12.7
stage 1 or 2 HTN
≥1 RF for CAD
ASCOT-BPLA 19,257 40–79 y/o Pts on ≥3 drug classes BP ≥140/90 mmHg OR pts ≥4 drug classes 48.5
≥3 CV RF
INVEST 22,576 ≥55 y/o Pts on ≥3 drug classes (HCT included) BP ≥140/90 mmHg 28.8
documented CAD
LIFE 9,222 55–80 y/o Pts on ≥3 drug classes (HCT included) BP ≥140/90 mmHg 53.9
EKG signs LVH
CONVINCE 16,476 ≥55 y/o Pts on ≥3 drug classes (HCT included) BP ≥140/90 mmHg 34.3
≥1 CV RF
BP, blood pressure; CAD, coronary artery disease; CV, cardiovascular; EKG, electrocardiogram; HCT, hydrochlorothiazide; HTN, hypertension; LVH, left ventricular
hypertrophy; Pts, patients; RF, risk factor; RH, resistant hypertension; y/o, years old.
known. For example, in a survey of more than 50,000 hypertensive
patients with at least three cardiovascular risk factors the detri-
mental effect was lower than expected, with an excess risk for
cardiovascular events (hazard ratio 1.18, 95% confidence inter-
val 1.10–1.26), especially non-fatal stroke (hazard ratio 1.26, 95%
confidence interval 1.10–1.45) and congestive heart failure (haz-
ard ratio 1.36, 95% confidence interval 1.23–1.51) in patients with
RH compared to non-resistant hypertensives (39).
Thus, even though the evidence collectively indicates that RH
implies an excess risk of cardiovascular events, the extent of this
increased risk varies widely, likely reflecting the variable definitions
of RH across studies.
PATHOGENESIS OF RESISTANT HYPERTENSION AND
POTENTIAL BENEFITS OF MINERALOCORTICOID RECEPTOR
ANTAGONISTS
In patients with uncontrolled BP pseudo-resistance must be
excluded beforehand. The latter can be secondary to: (1) poor
office BP measurement technique, (2) “white-coat” effect, which
encompasses up to 40% of patients with uncontrolled BP (4), (3)
non-adherence to the prescribed therapy [30–40% of subjects (7,
8)], or (4) a suboptimal anti-hypertensive regimen, owed to inap-
propriate drug associations or therapeutic inertia (40–42). Only
after exclusion of pseudo-resistance and of secondary hyperten-
sion patients can be labeled as having RH, whose most common
causes are: excessive salt intake and obesity. In our view, the diag-
nosis of RH should be regarded as a provisional classification of
the patient and by no means a long-time definition for the fol-
lowing reason: many patients with RH if properly investigated are
found to be affected by secondary forms of high BP.
Several substances or pharmacological agents can induce hyper-
tension or reduce the efficacy of anti-hypertensive therapies and
have been associated to RH (10). A special mention among
the pharmacological agents pertains to the non-steroidal anti-
inflammatory, oestro-progestinic, steroid, and immunosuppres-
sive drugs, because of their widespread use. Likewise, due to their
increasing diffusion a careful history on abuse substances, such as
cocaine and amphetamines, as well as alcohol and coffee, should
be elicited.
Compared to uncomplicated well controlled hypertensive
patients those with uncontrolled BP display a higher prevalence of
secondary hypertension, due to primary aldosteronism (7–20%)
(43, 44), renal artery stenosis (2–24%) (45, 46), and chronic kidney
diseases (30–40%) (31, 34, 36, 47), with rates varying across studies
because of the different selection criteria, cohorts, and diagnostic
work-up exploited.
Primary aldosteronism is the most frequent cause of secondary
hypertension (48, 49) in newly diagnosed referred consecutive
hypertensive patients and when surgically non-curable forms are
present its most appropriate treatment are MRAs. In the PAPY
study, including 1,125 consecutive hypertensive patients enrolled
at 18 referral centers throughout Italy, who were screened while
either on pharmacological wash-out or on CCB and/or doxazosin
treatment, the prevalence of primary hyperaldosteronism was 11.2
and 43% of these cases had an aldosterone-producing adenoma
(APA) (49). Of note, only 48% of patients with APA and 17%
of those with idiopathic hyperaldosteronism had hypokalemia
at clinical presentation. Moreover, even though the prevalence
of primary aldosteronism increased with the severity of hyper-
tension most cases were seen in stage I and stage II hyperten-
sion. These evidences contradict the fallacious perception that a
diagnosis of primary aldosteronism should be pursued only in
patients with hypokalemia (49). Because of the misconception
that primary aldosteronism is a disease of hypertensive patients
with hypokalemia and severe/resistant hypertension it goes mostly
unnoticed (49). Furthermore, the diagnostic work-up bears more
difficulties in patients on multiple drugs, most of which affect the
RAAS (50).
In addition to primary aldosteronism, most patients with RH
develop a secondary aldosteronism triggered by a diuretic-induced
sodium depletion, which activates the RAAS, similarly to what
happens with sodium restriction (17, 51). In this context, it is
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worth noting how MRAs can effectively counteract this effect and
improve BP control. Similarly, long-term use of RAAS inhibitors
(ACE-I and ARB) is known to be associated with angiotensin
II increase and ensuing aldosterone production, which can con-
tribute to resistance to the anti-hypertensive therapy. In fact,
whereas the acute effect of RAAS inhibitors is a decrease of aldos-
terone, in the long run aldosterone can increase to levels even
higher than pretreatment (52,53),as well documented in a relevant
proportion (10–53%) of the patients with heart failure or chronic
kidney disease on protracted ACE-I or ARB treatment (54).
The MR, besides its well-known effects in the kidney, has
extra-renal actions that could affect BP regulation (55), includ-
ing activation of the sympathetic nervous system (56), endothelial
dysfunction (57), and vasoconstriction (58) through stimulation
of the human vascular smooth muscle cells (59). Moreover, blacks
have lower plasma renin activity (PRA) and plasma aldosterone
levels than whites, but their BP is directly associated with the
plasma aldosterone concentration and increases with 9-α fludro-
cortisone administration, an effect that does not occur in whites
(60). Hence, collectively these observations suggest differences in
the individual sensitivity of the vasculature to MR activation (61).
Finally, the activity of the MR-dependent pathways can be
triggered without increases of plasma aldosterone levels through
mechanisms different from raised receptor sensitivity, such as
increased receptor expression or stimulation by other ligands
[reviewed in Ref. (62)], as for example angiotensin II (63–65) or
cortisol (62).
Excessive dietary salt intake with ensuing volume overload
is a well recognized risk factor for RH (66, 67) owing to its
pressor effect and its blunting of the BP-lowering action of anti-
hypertensive agents. According to the available studies 90% of the
patients with RH have some degree of plasma volume expansion
(68) and raised levels of brain-type and atrial natriuretic peptides
(69). The same studies also showed high levels of plasma aldos-
terone and aldosterone–renin ratio, and low PRA, which could
be explained either by the high prevalence of undetected primary
aldosteronism (43, 44) or by the secondary aldosteronism due to
diuretic treatment (69). Two different approaches relying on this
premises proved to be efficacious in RH patients: (1) the estimation
of body volume expansion by measurement of thoracic bioim-
pedance as a guide to up-titrate diuretics (70); (2) the sequential
blockade of the nephron by means of stepped addition of four
low-dose diuretics, spironolactone among others, to antagonize
the sodium and water reabsorption along the nephron (51).
Obesity (50–55%) is common in patients with RH (4, 34) and
is associated to suboptimal BP control as demonstrated by the
HYDRA study (71). The underlying pathophysiology of the BP ele-
vation in obese patients entails a combination of sodium retention,
activation of the sympathetic nervous system (72), sleep-related
breathing disorders, and relative hyperaldosteronism with ensuing
volume expansion (73).
Patients with RH bear an extensive, up to 70%, prevalence of
obstructive sleep apnea (OSA) (45, 74–76), which is increasingly
recognized as an important determinant of uncontrolled hyper-
tension. The improvements of BP control in affected subjects
undergoing efficacious treatment of OSA with continuous pos-
itive air pressure ventilation support a causal link between these
conditions (77, 78). The putative pathogenesis is possibly ascribed
to the increased upper airway resistance and intermittent hypoxia,
which activate the sympathetic nervous system and the RAAS,
as suggested by the association of its severity with plasma aldos-
terone levels (76) and by the improvement of OSA patients on
spironolactone treatment (79).
Taken together these evidences reveal the complexity of the
pathogenesis of RH and a key role for the MR in it, thus suggesting
the relevant role of MRA therapy in this field.
CURRENT THERAPIES FOR RESISTANT HYPERTENSION
Adherence to a low-sodium diet ranks first among the lifestyle
measures to be recommended to all hypertensive patients because
it is highly effective in decreasing both systolic and diastolic BP
(4–7 and 1–3 mmHg, respectively) as recently demonstrated (47,
80, 81) with effects even more striking in patients with RH (67).
Moreover, regular isotonic exercise should be included in the ther-
apeutic approach to RH in that it is able to decrease BP even in
subjects with low responsiveness to medical treatment (82).
Another point that has to be highlighted and pursued in RH
is that drug association therapy is typically more effective than
increasing the dose of each medication. This was clearly evidenced
in a meta-analysis of 354 randomized placebo-controlled trials
showing that doubling the anti-hypertensive agent dosage was less
effective in lowering systolic and diastolic BP than combination
therapy [2 and 1 mmHg vs. 6–7 and 3–4 mmHg, respectively (83)].
These results were later confirmed by a subsequent meta-analysis
(84) and in the OSCAR trial examining an intensified monother-
apy regimen with a high-dose ARB (40 mg olmesartan) and an
association approach with a low-dose ARB (20 mg olmesartan)
plus a dihydropiridinic CCB (amlodipine or azelnidipine) (85).
Despite a similar decrease of BP in the two treatment arms, com-
bination therapy reduced the incidence of cardiovascular events
and death in high-risk patients with a history of cardiovascular
morbidity at baseline.
Among diuretics, chlorthalidone, a long-acting thiazide-like
diuretic, is held to be more potent than hydrochlorothiazide in
lowering BP (86) and therefore should be preferred, according to
Messerli, over the latter, which at its usual dose of 12.5–25 mg is
inferior to other anti-hypertensive agents (87, 88). However, due
to its long half-life (50 h), which exposes to a carry-over effect
with daily assumption, it confers a higher risk of hypokalemia.
The chlorthalidone-induced hypokalemia was in fact suggested to
be a sign of undetected primary aldosteronism (89).
The ESH/ESC guidelines suggest that patients with RH and per-
sistently elevated BP values despite medical treatment optimiza-
tion should be considered for invasive procedures such as carotid
baroreceptor stimulation and renal denervation (see Table 4).
The former seems a promising technique, as evidenced by the
Rheos pivotal trial. This relatively large randomized controlled
trial showed a borderline significant greater SBP reduction in the
treatment arm compared to the placebo group (16 vs. 9 mmHg,
respectively, p= 0.08) (90). Regarding renal denervation, the high
expectations generated by the SYMPLICITY HTN-1 (91) and -
2 (92) trials were attenuated by the results of the SIMPLICITY
HTN-3 trial, which could not demonstrate an advantage of the
procedure compared to sham controls in patients with RH in part
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Table 4 | ESH/ESC guidelines on resistant hypertension invasive
treatment.
Recommendation Class Level
Invasive procedures may be considered in RH
patients if drug treatment is ineffective
IIb C
Invasive procedures should be carried out by
experienced operators; diagnosis and follow-up
should be restricted to hypertension centers
I C
Invasive procedures should be considered only in
truly RH patients with clinic SBD ≥160 mmHg
and DBP ≥110 mmHg and confirmed at ABPM
I C
ABPM, ambulatory blood pressuremonitoring; DBP, diastolic blood pressure; RH,
resistant hypertension; SBP, systolic blood pressure.
due to the larger than expected BP fall in the sham group, but,
interestingly enough, also for the higher rate of treatment with
MRAs in this trial than in the previous ones (93).
In conclusion, although in the definition of RH only the generic
term “diuretic” is mentioned, by no means all diuretics are equal
and a careful choice of the agent along with appropriate up-
titration of the dose(s) are key for bringing BP under control.
Among diuretics, MRAs deserve a special place for the multitude
of potential benefits they provide, so that some experts advocate
their use as a fourth line add-on drug in patients with RH (23, 94).
EVIDENCES THAT MINERALOCORTICOID RECEPTOR
ANTAGONISTS ARE EFFICACIOUS IN RESISTANT
HYPERTENSION
Treatment of hypertension with MRAs was introduced almost
40 years ago (95–97). Spironolactone proved to be as effective
as propranolol (95) and chlorthalidone (97), and remained effi-
cacious as an add-on therapy in patients already receiving a
diuretic (98), probably due to the blunting of the aldosterone
breakthrough effect. Eplerenone was developed in an attempt to
overcome the adverse effects of MRAs, including erectile dysfunc-
tion and gynecomastia, which depends on their anti-androgenic
effects (99–101). This compound was suggested to be more selec-
tive (102) and at least as effective as losartan (103) or even superior
to the former in patients with low-renin hypertension (104) and
in those of African-American descent (103). Eplerenone was also
shown to be as effective as enalapril (105, 106) and amlodipine
(107) as an add-on therapy to ACE-I or ARB monotherapy (108).
However, it is shorter acting and less potent than spironolactone,
canrenone, and potassium canreonate. Moreover, when used at
doses equipotent as spironolactone on BP, it was found to cause
estrogen-like effects. Of note, the EVALUATE study, a multicenter,
randomized, double blind clinical trial of patients with hyperten-
sion and stage 2 and 3 chronic kidney disease, showed that both
BP and microalbuminuria were significantly lower over 52 weeks
of follow-up in patients assigned to a low-dose eplerenone once
a day than in those receiving placebo, both on top of treatment
with an ACE-I or an ARB. No hyperkalemia, gynecomastia, or
erectile dysfunction were observed with such a low-dose of this
MRA (109).
Several authors have highlighted the value of MRAs in patients
with RH by virtue of cohort studies (110–116) [reviewed by Ref.
(117, 118)] and of placebo-controlled clinical trials (51, 119–122),
which are held to provide harder evidences, as outlined in the
following paragraphs (Table 5).
The first placebo-controlled trial testing the efficacy of MRAs
in RH was the ASPIRANT, which included 117 patients random-
ized to 25 mg of spironolactone or placebo and assessed with 24 h
ABPM (119). After 8 weeks of treatment the MRA decreased mean
daytime systolic BP of 5 mmHg (95% CI 10–0.8 mmHg), e.g., the
primary endpoint, and microalbuminuria of 4.4 mg/day, while it
did not reduce mean daytime diastolic BP (1 mmHg, 95% CI−4–
2 mmHg). This trial was stopped prematurely after reaching the
primary endpoint in an ad interim analysis. However, 24% of the
patients enrolled were found to have primary aldosteronism at
further evaluation, which most likely contributed to the favorable
results of the study. Moreover, patients with glomerular filtration
rate lower than 40 ml/min were excluded from the ASPIRANT trial
owing to the potential risks of hyperkalemia.
Therefore, a randomized placebo-controlled trial was per-
formed by Abolghasmi et al. to prove the efficacy of MRA therapy
in chronic kidney disease patients (120). The authors randomized
41 patients with chronic kidney disease (glomerular filtration rate
between 50 and 25 ml/min) to 25–50 mg/day of spironolactone
or placebo and found that at 6 weeks the MRA decreased sys-
tolic and diastolic BP of 33 and 13 mmHg, respectively, whereas
placebo did not affect BP. It is worth highlighting that patients
with secondary hypertension other than chronic kidney disease
were excluded from the study and that only one out of 19 cases
receiving MRA treatment developed hyperkalemia (>5.5 mmol/l).
Despite the relevance of these results some drawbacks ought to be
mentioned, such as the use of a subjective way to assess therapeutic
efficacy of MRA like office BP in lieu of the more objective ABPM
and the lack of details on randomization and blinding procedures.
To test the non-inferiority of a sequential nephron blockade
strategy (by means of the sequential addition of spironolactone,
furosemide, and amiloride) vs. a sequential renin–angiotensin
system blockade (by virtue of add-on ramipril and bisopro-
lol at increasing doses) Bobrie et al. randomized 167 patients
with RH, treated with irbesartan 300 mg/day, hydrochlorothiazide
12.5 mg/day, and amlodipine 5 mg/day (51). The trial demon-
strated that the sequential nephron blockade was more efficacious
than the renin–angiotensin system blockade at decreasing BP in
these patients as assessed by ABPM. Moreover, it showed a sig-
nificant decrease in systolic and diastolic BP in patients treated
with spironolactone 25 mg/day as compared to ramipril 5 mg/day.
These results are potentially important for RH patients but carry
two main limitations: (i) the trial was not specifically designed to
test the efficacy of spironolactone; (ii) when either spironolactone
or ramipril were added, patients were not receiving a maximal dose
of diuretic and CCB and therefore, strictly speaking, they did not
meet the RH definition.
To test the efficacy in lowering mean sitting systolic BP of a
new compound, the aldosterone synthase inhibitor LCI699, Karns
et al. randomized 155 patients to receive a placebo or the active
drug (122). The study failed his primary endpoint in that it could
not demonstrate a significant decrease of BP with the aldosterone
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Table 5 | Randomized controlled trials comparing mineralocorticoid receptor antagonists vs. placebo in resistant hypertension patients.
Study Pts
(n°)
Pts
characteristics
End points MRA Dose
mg/day
Control Follow up
weeks
Results
Vaclavík
et al.
117 RH pts Decrease of daytime SBP and
DBP on ABPM
Spironolactone 25 Placebo 8 5.4 mmHg decrease of
daytime SBP
Abolghasmi
et al.
41 RH pts with
CKD
n/a Spironolactone 25–50 Placebo 12 30/8 mmHg SBP and DBP
decrease (office BP)
Bobrie
et al.
167 RH pts Non-inferiority of SNB relative
to SRASB in reducing daytime
ambulatory SBP
Spironolactone 25 Ramipril 12 Significant decrease of home
SBP and DBP at 4 w with
spironolactone
Oxlund
et al.
119 RH pts with
type 2 DM
Reduction of daytime SBP
and DBP at ABPM
Spironolactone 25 Placebo 16 8.9/3.7 mmHg daytime SBP
and DBP decrease (ABPM)
Karns
et al.
155 RH pts Mean sitting SBP of LCI vs.
placebo
Eplerenone 100 LCI699,
placebo
8 No difference LCI699 vs.
placebo; decrease of
14.7/9.4 mmHg, SBP and
DBP, with eplerenone (ABPM)
ABPM, ambulatory blood pressure monitoring; CKD, chronic kidney disease; DBP, diastolic blood pressure; DM, diabetes mellitus; n/a, not available; Pts, patients;
RH, resistant hypertension; SBP, systolic blood pressure; SNB, sequential nephron blockade; SRASB, sequential renin–angiotensin system blockade; w, weeks.
synthase inhibitor at various doses compared to placebo. However,
interestingly enough, it showed that after 8 weeks eplerenone
induced a significant decrease of systolic and diastolic BP com-
pared to placebo (14–15 and 9–11 mmHg, respectively) as assessed
at ABPM. Despite not being originally designed to compare MRA
therapy with placebo, this study is important in that it extends to
the whole MRA class the efficacy in RH.
Finally, Oxlund et al. tested in a randomized placebo-controlled
trial the effect of a MRA in reducing BP at ABPM in 119 RH
patients with type two diabetes mellitus (121). Using ABPM, the
study showed that spironolactone at a mean dose of 35 mg/day
significantly reduced systolic and diastolic BP by 9 and 4 mmHg,
respectively. The MRA treatment was three times more efficacious
than placebo both in lowering BP values at target and in decreasing
microalbuminuria.
In summary, both observational studies and randomized tri-
als support the conclusion that MRAs are effective in patients
with RH. It has to be acknowledged, however, that these trials had
few drawbacks including small sample size (51, 119–122), absence
of a systematic exclusion of patients with secondary hyperten-
sion (119–122), white-coat hypertension (120, 122), and treat-
ment non-adherence (51, 119–122), and endpoints were often not
specifically focused to demonstrate the effect MRAs (51, 122).
Despite these limitations, the evidence for efficacy of the MRA in
patients with RH now appears to be compelling thus strengthen-
ing the proposal both of including MRAs as a cornerstone therapy
in patients with difficult-to-control hypertension and the need
of lack of response to a MRA as a condicio sine qua non for the
definition of RH (Figure 1).
PREDICTORS OF MINERALOCORTICOID RECEPTOR
ANTAGONISTS EFFICACY
The main issue in dealing with RH is how to select the appro-
priate treatment for most patients, which implies finding some
predictors of their efficacy.
In treatment-naïve hypertensive patients (123) and in those
on multiple drugs (112, 124) serum potassium values below 4.0–
4.5 mmol/l were reported to forecast MRAs efficacy. However, even
though low serum potassium could indicate patients with underly-
ing primary or secondary hyperaldosteronism, not all the literature
concur with this finding (119).
To predict the response to MRA almost 40 years ago Karlberg
et al. observed that spironolactone was more effective in pre-
viously untreated patients with low-renin (PRA <1.0 ng/ml/h)
essential hypertension (95), a finding subsequently confirmed
(123) and extended to patients with RH tested while on anti-
hypertensive treatment (119). A correlation was also reported
between the aldosterone–renin ratio and MRA efficacy in patients
undergoing MRA monotherapy (123) and with RH (119). How-
ever, other studies including untreated stage 1 or 2 hyperten-
sives (105), or enrolling subjects with low-renin hypertension
(PRA <1.0 ng/ml/h) (104), patients undergoing treatment with
eplerenone as an add-on drug to ACE-I or ARB (125), and patients
with multi-drug therapy (126) or with RH (111, 123) dispute these
findings.
In conclusion, it remains still controversial if renin, aldos-
terone, and the aldosterone–renin ratio can predict the BP
response to MRA in patients already on anti-hypertensive treat-
ment (104, 105, 111, 119, 123, 125, 126). Most likely this is
because these measurements are deeply biased by the concomitant
anti-hypertensive treatment (125). In keeping with this inter-
pretation, data were more consistent in treatment-naïve patients
where these measurements seem to have a role (95, 123). The
use of serum potassium level as a predictor of efficacy could
be more reliable; however, its usefulness can be affected by the
cut-off value of baseline serum potassium chosen in the dif-
ferent studies as a threshold for up-titrating the MRA treat-
ment (94). In fact, adequate dosing of the MRA is a cru-
cial step for increasing the rate of patients’ response to this
treatment (55).
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FIGURE 1 | Mineralocorticoid receptor antagonists treatment algorithm in patients with a provisional resistant hypertension diagnosis. BP, blood
pressure; eGFR, estimated glomerular filtration rate; K+, potassium; MRA, mineralocorticoid receptor antagonist; Na+, sodium; RH, resistant hypertension.
CONTRAINDICATIONS TO MINERALOCORTICOID RECEPTOR
ANTAGONISTS THERAPY
Despite being usually well-tolerated MRAs should be cautiously
prescribed to special populations. Pregnant and breast-feeding
women should avoid MRAs, which cross the placenta, especially
in the first trimester, and enter the breast milk, due to their anti-
androgenic effect. Monitoring of side effects should be carried out
in male subjects, who can complain of erectile dysfunction and
gynecomastia.
Due to a higher probability of side effects elderly (≥75
years) and chronic renal disease (glomerular filtration rate
<60 ml/min/1.73 m2) patients should be prescribed MRAs judi-
ciously. We suggest to halve the starting dose of the drug and to
check renal function, serum potassium, and sodium levels after
1 week and after every dose increase. Using these precautions
the prescription of MRAs appears safe as demonstrated by trials
conducted in patients with chronic renal insufficiency [glomeru-
lar filtration rate ≥25–50 ml/min/1.73 m2 (109, 120)] where
hyperkalemia occurred only sporadically.
Serum potassium testing is mandatory before MRA therapy
prescription, in that hyperkalemia is a serious side effect of these
drugs, which therefore must not be given to hyperkalemic patients.
However, in normokalemic patients with regular testing these
medications are safe as showed by clinical trials completed in
subjects with RH (119) or chronic kidney disease (109). As a
rule of thumb, it is a safe practice to avoid MRAs administra-
tion to patients with hyperkalemia (≥5.5 mmol/l) and to decrease
its dose when at reassessment the serum potassium increases
≥5.5 mmol/l, while discontinuing indefinitely this therapy if it
increases ≥6.0 mmol/l.
Finally, a particular mention deserves the concurrent pre-
scription of MRAs with non-steroidal anti-inflammatory agents
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because of their extensive use. These agents reduce the anti-
hypertensive treatment efficacy and, furthermore, induce a
hyporeninemic hypoaldosteronism thus raising the risk of severe
and life-threatening hyperkalemia (127).
CONCLUSION
Resistant hypertension is an increasingly recognized problem in
hypertension treatment owing to its association with a worse prog-
nosis. Based on increasing evidences demonstrating the contribu-
tion of aldosterone to its pathogenesis, few uncontrolled studies
and randomized clinical trials were completed on this field and
demonstrated the beneficial role of the mineralocorticoid receptor
antagonists. Therefore, based on these evidences a strong recom-
mendation should be made to advocate their use as a “must” in
patients with resistant hypertension.
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